0001209191-23-058061.txt : 20231211
0001209191-23-058061.hdr.sgml : 20231211
20231211163602
ACCESSION NUMBER: 0001209191-23-058061
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231207
FILED AS OF DATE: 20231211
DATE AS OF CHANGE: 20231211
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Eydelman Mikhail
CENTRAL INDEX KEY: 0001918033
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39323
FILM NUMBER: 231478619
MAIL ADDRESS:
STREET 1: C/O VAXCYTE, INC.
STREET 2: 825 INDUSTRIAL ROAD, SUITE 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vaxcyte, Inc.
CENTRAL INDEX KEY: 0001649094
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 464233385
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 650-837-0111
MAIL ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
FORMER COMPANY:
FORMER CONFORMED NAME: SutroVax, Inc.
DATE OF NAME CHANGE: 20150724
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-07
0
0001649094
Vaxcyte, Inc.
PCVX
0001918033
Eydelman Mikhail
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, SUITE 300
SAN CARLOS
CA
94070
0
1
0
0
SVP, Gen Counsel & Corp Sec
1
Common Stock
2023-12-07
4
M
0
10000
21.41
A
31035
D
Common Stock
2023-12-07
4
S
0
10000
56.50
D
21035
D
Common Stock
2023-12-07
4
F
0
325
56.78
D
20710
D
Stock Option (right to buy)
21.41
2023-12-07
4
M
0
10000
0.00
A
2032-05-08
Common Stock
10000
195000
D
Includes 548 shares acquired under the Vaxcyte, Inc. Employee Stock Purchase Plan on November 17, 2023.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023.
Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.
1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.
Mikhail Eydelman, by /s/ Ron A. Metzger, Attorney-in-Fact
2023-12-11